Novo CEO pressed by Senate to chop costs of obesity, diabetes drugs CEO Lars Fruergaard Jørgensen explained to lawmakers the company would take into consideration new talks with insurers with regards to the listing selling prices of Wegovy and copyright whenever they pledge to maintain the medicines on their formularies. https://buschlightpeachnutritionf27160.smblogsites.com/30663779/the-ultimate-guide-to-healthcare-news